Literature DB >> 31811912

Choking agents and chlorine gas - History, pathophysiology, clinical effects and treatment.

Tobias Zellner1, Florian Eyer2.   

Abstract

INTRODUCTION: Choking agent exposure, among them chlorine gas, occurs in household or industrial accidents, chemical warfare and terrorist attacks. AIMS: Review of published animal and human data regarding the history, pathophysiology, clinical effects and management of chlorine exposure. PATHOPHYSIOLOGY: Highly soluble agents cause quick upper respiratory tract symptoms. Chlorine gas has a medium solubility, also causing delayed lower airway symptoms, mainly due to its oxidizing potential by releasing hypochlorous and hydrochloric acid, but also by interacting with Transient Receptor Potential channels. SYMPTOMS: Eyes may show conjunctival injection, abrasions and corrosions. Burns of the oronasal mucosa and trachea can occur. Dyspnea, bronchospasm and possible retrosternal pain occur frequently. Glottis edema or laryngospasm are acute life-threatening emergencies. Chlorine gas can cause toxic pneumonitis, lung edema and acute respiratory distress syndrome (ARDS). MANAGEMENT: General management includes physical examination, pulse oximetry and arterial blood gases. Eyes should be irrigated, humidified oxygen and inhalative bronchodilators administered. An EKG, cardiac enzymes and complete-blood-count should be obtained if there is retrosternal pain. Routine chest x-ray is not recommended - except if pulmonary edema is suspected. Laryngoscopy should be performed if glottis edema is suspected. Sodium bicarbonate inhalation after chlorine gas inhalation is discussed controversially. Mechanical ventilation with continuous-positive-airway-pressure or intubation/tracheotomy with high positive-end-expiratory-pressure may be necessary. Glucocorticoids for prevention of pulmonary edema should be applied restrictively. Prophylactic antibiotics are not recommended. In severe ARDS, extracorporeal membrane oxygenation (ECMO) can be considered.
CONCLUSION: Treatment is mainly symptom oriented. New and promising therapies are in development.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acute lung injury; Acute respiratory distress syndrome; Chemical warfare; Chlorine gas; Choking agents; Treatment

Mesh:

Substances:

Year:  2019        PMID: 31811912     DOI: 10.1016/j.toxlet.2019.12.005

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  6 in total

1.  Histone H4 aggravates inflammatory injury through TLR4 in chlorine gas-induced acute respiratory distress syndrome.

Authors:  Yanlin Zhang; Jian Zhao; Li Guan; Lijun Mao; Shuqiang Li; Jinyuan Zhao
Journal:  J Occup Med Toxicol       Date:  2020-10-08       Impact factor: 2.646

2.  Wartime toxicology: the spectre of chemical and radiological warfare in Ukraine.

Authors:  P R Chai; Y Berlyand; E Goralnick; C E Goldfine; M J VanRooyen; D Hryhorczuk; T B Erickson
Journal:  Toxicol Commun       Date:  2022-04-01

3.  A case of acute inhalation injury caused by premeditated chlorine gas exposure.

Authors:  Takuma Katano; Hiroto Murao; Toshio Kato; Akihito Kubo; Satoru Ito
Journal:  Respirol Case Rep       Date:  2021-03-26

4.  Histone H4 induces heparan sulfate degradation by activating heparanase in chlorine gas-induced acute respiratory distress syndrome.

Authors:  Yanlin Zhang; Fei Xu; Li Guan; Ming Chen; Yiran Zhao; Lixia Guo; Xiao Li; Yimu Zheng; Ai Gao; Shuqiang Li
Journal:  Respir Res       Date:  2022-01-24

5.  Clinical Features and Outcomes of Acute Chlorine Gas Inhalation; a Brief Report.

Authors:  Taymmia Ejaz; Sheema Saadia; Safia Akhlaq; Adil Aziz; Muhammad Arslan Ahmed; Aisha Fareed Siddiqui
Journal:  Arch Acad Emerg Med       Date:  2022-02-14

6.  Chlorine poisoning caused by improper mixing of household disinfectants during the COVID-19 pandemic: Case series.

Authors:  Guo-Dong Lin; Jie-Yi Wu; Xiao-Bo Peng; Xiao-Xia Lu; Zhong-Ying Liu; Zhi-Guo Pan; Ze-Wu Qiu; Jian-Guang Dong
Journal:  World J Clin Cases       Date:  2022-09-06       Impact factor: 1.534

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.